^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NRG1 overexpression

i
Other names: NRG1, GGF, HGL, HRG, NDF, NRG1-IT2, Neuregulin 1, Heregulin
Entrez ID:
4ms
NRG1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by NRG1 inhibition in esophageal squamous cell carcinoma. (PubMed, Biochem Pharmacol)
Finally, we show that afatinib (FDA approved cancer growth blocker) could inhibit ESCC with overexpressed NRG1 and down-regulation of NRG1 along with afatinib treatment provides higher efficient strategy. This study uncovers the critical role and molecular mechanism of NRG1 in ESCC tumorigenesis and metastasis, suggesting its potential as a novel biomarker for ESCC treatment.
Journal
|
NRG1 (Neuregulin 1) • MMP9 (Matrix metallopeptidase 9)
|
NRG1 overexpression
|
Gilotrif (afatinib)
1year
Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia. (PubMed, Nat Commun)
Mice with modest-temporary hyperglycemia, induced by low-dose short-exposure streptozotocin, display accelerated tumor growth and lapatinib resistance, whereas combining lapatinib with N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S42 phenylglycine t-butyl ester (DAPT) ameliorates tumor growth under these modest hyperglycemic conditions by inhibiting NOTCH and EGFR superfamilies. NOTCH activity is correlated with NRG1 levels, and high NRG1 levels predicts poor outcomes, particularly in HER2-positive breast cancer patients. Our findings highlight the hyperglycemia-linked epigenetic modulation of NRG1 as a potential therapeutic strategy for treating breast cancer patients with diabetes.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1) • EP300 (E1A binding protein p300) • SETD1A (SET Domain Containing 1A)
|
HER-2 positive • NRG1 overexpression
|
lapatinib
almost2years
Effects of Oncogene Neuregulin 1 on Breast Cancer Cells. (PubMed, Pak J Biol Sci)
<b></b> The NRG1 can promote the malignant function of breast cancer cells by augmenting migration and invasion abilities. High expression of NRG1 remarkably suppressed the apoptosis of breast cancer cells.
Journal
|
NRG1 (Neuregulin 1)
|
NRG1 fusion • NRG1 overexpression • NRG1 fusion
over3years
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. (PubMed, Int J Mol Sci)
In vivo treatment with a FASN inhibitor restored the anti-tumor activity of tamoxifen and fulvestrant against fast-growing, hormone-resistant MCF-7/HRG xenograft tumors in mice. Overall, these findings implicate FASN as a key enabler for endocrine resistance in HRG+/HER2- breast cancer and highlight the therapeutic potential of FASN inhibitors for the treatment of endocrine therapy-resistant luminal-B breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1) • FASN (Fatty acid synthase)
|
ER positive • HER-2 negative • HER-2 expression • NRG1 overexpression
|
tamoxifen • fulvestrant
almost4years
[VIRTUAL] Anti-cancer efficacy of an anti-ErbB3 antibody, ISU104, against the cancers with NRG1-overexpression, NRG1-fusion, or oncogenic ErbB3 mutations (AACR-II 2020)
Potential impacts of other genetic alterations on the anti-cancer efficacy of ISU104 were also investigated. Overall, the presented data suggest that ISU104, an anti-ErbB3 agent in the early stage of clinical development, can be applied for the treatment of the solid tumors expressing high level of NRG1 or harboring genetic alterations such as NRG1-fusion or oncogenic ErbB3 mutations.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)
|
NRG1 fusion • ERBB3 mutation • NRG1 overexpression
|
barecetamab (ISU104)